Indegene reported a flat June-quarter profit despite a nearly 40% jump in revenue, as weaker operating margins offset the benefits of strong business growth. Revenue crossed ₹1,000 crore for the quarter, while profitability came under pressure due to a sharp decline in margins.

Indegene is a digital-first, AI-driven life sciences commercialisation company headquartered in Bangalore, India. The firm provides a range of services across clinical development, commercialisation, and enterprise operations to global pharmaceutical, biotechnology, and medical device companies. The life sciences outsourcing sector has seen sustained demand as pharmaceutical companies increasingly delegate non-core functions to specialised providers. Indegene went public on the Indian stock exchanges in 2024, making this among its early quarterly results as a listed entity.

The company's first-quarter results highlight a divergence between top-line expansion and bottom-line performance. Despite the substantial revenue increase, the contraction in operating margins meant that net profit saw little to no year-on-year change. Margin pressure has been a broader theme across India's services sector, where wage inflation and talent costs have weighed on profitability at multiple firms. For Indegene, this pattern underscores the cost pressures and investment requirements that can accompany rapid revenue growth in the life sciences services space. Whether margins stabilise in subsequent quarters as the company scales will be a key metric for investors tracking the newly listed stock.

Source: CNBC-TV18 Markets